Age-related macular degeneration.

Area of Science:

• Ophthalmology
• Retinal Diseases
• Vision Science

Background:

• Age-related macular degeneration (AMD) is a primary cause of severe, irreversible vision loss in individuals over 50 in the US.
• The nonexudative stage of AMD involves drusen and geographic atrophy, potentially progressing to neovascular AMD.
• The exudative stage of AMD is responsible for severe visual loss in most affected patients.

Purpose of the Study:

• To review the current understanding of age-related macular degeneration (AMD), focusing on its stages and treatment limitations.
• To highlight the challenges in treating exudative AMD and the need for further research.

Main Methods:

• Literature review of age-related macular degeneration (AMD) pathogenesis and current treatment modalities.
• Analysis of the efficacy and limitations of existing treatments for both nonexudative and exudative AMD.
• Evaluation of the current status of research into novel treatments for AMD.

Main Results:

• Current treatments for AMD are effective only for a small subset of patients with specific choroidal neovascular membrane (CNVM) characteristics.
• Even with successful treatment, visual loss is often temporary due to recurrent CNVMs.
• Low vision aids are the primary treatment for most patients with exudative AMD.

Conclusions:

• Most patients with exudative AMD will experience central visual impairment despite current therapeutic advancements.
• Further research is crucial for understanding AMD pathogenesis and developing effective treatments and preventative strategies.
• Investigational treatments are being explored for CNVMs closer to the foveal center.